Brief communication

**CSF sTREM2 is elevated in a subset in GRN-related frontotemporal dementia**

Emma L. van der Ende\textsuperscript{a}, Estrella Morenas-Rodriguez\textsuperscript{b,c}, Corey McMillan\textsuperscript{d}, Murray Grossman\textsuperscript{d}, David Irwin\textsuperscript{d}, Raquel Sanchez-Valle\textsuperscript{e}, Caroline Graff\textsuperscript{f,g}, Rik Vandenbergh\textsuperscript{h}, Yolande A.L. Pijnenburg\textsuperscript{i}, Robert Laforce\textsuperscript{j}, Isabelle Le Ber\textsuperscript{k,l}, Alberto Lleo\textsuperscript{m}, Christian Haass\textsuperscript{b,c,n}, Marc Suarez-Calvet\textsuperscript{b}, John C. van Swieten\textsuperscript{a}, Harro Seelaar\textsuperscript{a,*}

\textsuperscript{a}Alzheimer Center Rotterdam and Dept. of Neurology, Erasmus University Medical Center, Rotterdam, the Netherlands
\textsuperscript{b}German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany
\textsuperscript{c}Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universität München, Munich, Germany
\textsuperscript{d}Dept. of Neurology, Penn Frontotemporal Degeneration Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
\textsuperscript{e}Alzheimer’s Disease and Other Cognitive Disorders Unit, Hospital Clinic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain
\textsuperscript{f}Karolinska Institutet, Dept. NIV, Division of Neurogeriatrics, Bioclinicum, Stockholm, Sweden
\textsuperscript{g}Unit of Hereditary Dementia, Theme Aging, Karolinska University Hospital-Solna, Stockholm, Sweden
\textsuperscript{h}Laboratory for Cognitive Neurology, Department of Neurosciences, Leuven Brain Institute, Leuven, Belgium
\textsuperscript{i}Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
\textsuperscript{j}Clinique Interdisciplinaire de Mémoire du CHU de Québec, Reference Centre for Rare or Early Onset Dementias, IM2A, Department of Neurology, Hôpital La Pitié-Salpêtrière, Paris, France
\textsuperscript{k}Sorbonne Université, Paris Brain Institute, Institut du Cerveau, ICM, Inserm U1127, CNS UMR 7225, APHP, Hôpital Pitié-Salpêtrière, Paris, France
\textsuperscript{l}Neurology Department, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain
\textsuperscript{m}Munich Cluster for Systems Neurology (SyNergy), Munich, Germany

**A R T I C L E   I N F O**

Article history:
Received 18 December 2020
Accepted 27 February 2021
Available online 4 March 2021

Keywords:
Frontotemporal dementia
Biomarker
Cerebrospinal fluid
Microglia
sTREM2

**A B S T R A C T**

Excessive microglial activation might be a central pathological process in GRN-related frontotemporal dementia (FTD-GRN). We measured soluble triggering receptor expressed on myeloid cells 2 (sTREM2), which is shed from disease-associated microglia following cleavage of TREM2, in cerebrospinal fluid of 34 presymptomatic and 35 symptomatic GRN mutation carriers, 6 presymptomatic and 32 symptomatic C9orf72 mutation carriers and 67 healthy noncarriers by ELISA. Although no group differences in sTREM2 levels were observed (GRN: symptomatic [median 5.2 ng/mL, interquartile range [3.9–9.2]] vs. presymptomatic [4.3 ng/mL [2.6–6.1]] vs. noncarriers [4.2 ng/mL [2.6–5.5]; \( p = 0.059; \) C9orf72: symptomatic [4.3 [2.9–7.0]] vs. presymptomatic [3.2 [2.2–4.2]] vs. noncarriers: \( p = 0.294 \)), high levels were seen in a subset of GRN, but not C9orf72, mutation carriers, which might reflect differential TREM2-related microglial activation. Interestingly, 2 presymptomatic carriers with low sTREM2 levels developed symptoms after 1 year, whereas 2 with high levels became symptomatic after >5 years. While sTREM2 is not a promising diagnostic biomarker for FTD-GRN or FTD-C9orf72, further research might elucidate its potential to monitor microglial activity and predict disease progression.

© 2021 The Authors. Published by Elsevier Inc.

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)

1. Introduction

Frontotemporal dementia (FTD) is frequently caused by autosomal dominant genetic mutations in granulin (GRN).

Although the exact mechanisms by which GRN mutations lead to FTD are poorly understood, accumulating evidence suggests a role for dysregulation of microglial homeostasis (Bright et al., 2019; Chitramathu et al., 2017). GRN\textsuperscript{-/-} mice display excessive microglial activation with subsequent release of proinflammatory factors and neuronal loss (Lui et al., 2016; Martens et al., 2012; Tanaka et al., 2013), and suppression of genes characteristic for homeostatic microglia.
(Götzl et al., 2019), whereas GRN overexpression reduces microglial recruitment following nerve injury (Altmann et al., 2016). Biomarkers that accurately reflect microglial activity in vivo are currently lacking and might provide more insight into disease pathogenesis, as well as measure treatment effect in clinical trials aiming to restore immune dysregulation.

Triggering receptor expressed on myeloid cells 2 (TREM2) is a membrane-bound receptor expressed by microglia which regulates the transition from homeostatic to disease-associated microglia (Keren-Shaul et al., 2017; Kleinberger et al., 2014; Schleipckow et al., 2017). Cleavage of its extracellular domain produces a soluble fragment, sTREM2, which is measurable in cerebrospinal fluid (CSF) (Piccio et al., 2008). CSF sTREM2 levels likely reflect cerebral TREM2 expression and TREM2-triggered microglial activity (Ewers et al., 2020; Ewers et al., 2019; Keren-Shaul et al., 2017; Suárez-Calvet et al., 2019). Elevated sTREM2 levels have been observed mainly in the prodromal stages of Alzheimer’s disease (AD) (Liu et al., 2018; Ma et al., 2020; Suárez-Calvet et al., 2019). Reports of sTREM2 levels in FTD are inconsistent (Heslegrave et al., 2016; Kleinberger et al., 2014; Piccio et al., 2016), but high levels have been reported in a few FTD-GRN cases (Woollacott et al., 2018).

In the present study, we measured CSF sTREM2 in an international cohort of presymptomatic and symptomatic GRN mutation carriers and noncarriers to determine its value as a biomarker in FTD-GRN. To study potential gene-specificity, we additionally measured sTREM2 in carriers of a C9orf72 repeat expansion, the most common genetic cause of FTD.

2. Methods

Subjects were recruited from 8 research centers in Europe and the USA through familial FTD studies. We included 34 presymptomatic and 35 symptomatic GRN mutation carriers, 6 presymptomatic and 32 symptomatic C9orf72 mutation carriers, and 67 healthy noncarriers from GRN or C9orf72 mutation families. Subjects were classified as symptomatic if they met international consensus criteria for behavioral variant FTD, primary progressive aphasia or amyotrophic lateral sclerosis (ALS) (Brooks et al., 2000; Gorno-Tempini et al., 2011; Rascovsky et al., 2011). Symptom onset and disease duration were based on caregivers’ estimations of the emergence of first symptoms. Subjects had no known neurological or immunological co-morbidities. Global cognitive functioning was scored using the Mini Mental State Examination (MMSE).

CSF was collected in polypropylene tubes, centrifuged and stored at -80°C within 2 hours after withdrawal. sTREM2 levels were measured using an ELISA as previously described (Kleinberger et al., 2014). Samples were randomly distributed across plates and measured in duplicate; the median coefficient of variation (CV) of duplicate samples was 3.6%. One sample with a duplicate CV > 15% was excluded. Samples were measured in 2 batches (median between-batch CV 4%) in the German Center for Neurodegenerative Diseases (DZNE), Munich, Germany. Laboratory technicians were blinded to all clinical and genetic information.

Statistical analyses were performed in IBM SPSS Statistics 24 applying a significance level of 0.05 (2-sided). Demographic variables were compared using Kruskal-Wallis tests for numerical variables and χ² tests for categorical variables. Group comparisons of sTREM2 levels were performed by Mann Whitney U tests or Kruskal-Wallis tests as the data were not normally distributed. After log-transformation, sTREM2 levels were normally distributed, as confirmed by the Shapiro-Wilk test, and group comparisons were additionally performed by ANCOVA with correction for age, gender and assay batch. Spearman’s rho was used for correlational analyses. Bonferroni correction for multiple testing was applied where appropriate.

3. Results

3.1. Demographics

Subject characteristics are shown in Table 1. In both genetic groups (GRN and C9orf72), symptomatic mutation carriers were older at CSF collection than presymptomatic carriers and noncarriers (p < 0.001). sTREM2 levels were positively correlated with age across the entire cohort (rₛ = 0.271, p < 0.001) and in noncarriers alone (rₛ = 0.247, p = 0.044) but not in symptomatic GRN or C9orf72 mutation carriers (GRN: rₛ = 0.020, p = 0.911; C9orf72: rₛ = 0.206, p = 0.258) (supplementary Fig. 1). No differences were found in sTREM2 levels between males and females (p = 0.470).

3.2. sTREM2 levels in GRN mutation carriers

No significant differences in sTREM2 levels were seen in symptomatic GRN mutation carriers (median 5.2 ng/mL, interquartile range [3.9–9.2]) compared to presymptomatic carriers (4.3 ng/mL [2.6–6.1]) and noncarriers (4.2 ng/mL [2.6–5.5]) (p = 0.059 by Kruskal-Wallis test; p = 0.513 by ANCOVA) (Fig. 1). sTREM2 levels did not correlate with disease duration (rₛ = 0.210, p = 0.226) or MMSE score (rₛ = -0.364, p = 0.057, n = 28) among symptomatic carriers. Furthermore, no significant differences in sTREM2 levels were seen between the various FTD phenotypes (p = 0.830) (Table 1).

Three presymptomatic GRN mutation carriers developed FTD respectively 1 year, 1.2 years, and 7 years after CSF collection (Fig. 1). In addition, one presymptomatic GRN carrier developed mild behavioral abnormalities and cognitive deficits 5 years after CSF col-
lecion, although clinical diagnostic criteria for FTD were not fulfilled.

Visual inspection of Fig. 1 revealed high sTREM2 levels in 8 symptomatic GRN mutation carriers (≥10 ng/mL). We did not identify any association with specific clinical or genetic features in these subjects (i.e., disease severity or duration, phenotype, age at symptom onset, genetic mutation) (supplementary Table 1).

3.3. sTREM2 levels in C9orf72 mutation carriers

No significant differences in sTREM2 levels were seen between symptomatic (median 4.3 ng/mL [2.9–7.0]) and presymptomatic (3.2 ng/mL [2.2–4.2]) C9orf72 mutation carriers or noncarriers (p = 0.294 by Kruskal-Wallis test; p = 0.433 by ANCOVA) (Fig. 1). Results were unchanged after exclusion of subjects with isolated ALS (n = 4) or FTD with ALS (n = 9). sTREM2 levels did not correlate with disease duration (r_s = 0.199, p = 0.275) or MMSE score (r_s = -0.037, p = 0.856, n = 27) among symptomatic carriers.

3.4. Comparison between GRN and C9orf72 mutation carriers

sTREM2 levels did not differ between symptomatic GRN and C9orf72 mutation carriers (p = 0.196) or between presymptomatic GRN and C9orf72 mutation carriers (p = 0.288) (both by Mann-Whitney U tests).

4. Discussion

The present study revealed no significant differences in CSF sTREM2 levels between presymptomatic and symptomatic GRN or C9orf72 mutation carriers and noncarriers. Although the lack of group differences and overlap in sTREM2 levels between groups preclude its value as a diagnostic biomarker, a remarkable degree of variability in sTREM2 levels was observed among GRN mutation carriers, which warrants further study.

Several GRN mutation carriers had very high sTREM2 levels, whereas sTREM2 levels among C9orf72 carriers and noncarriers appeared to be more consistent, which is in line with previous findings (Woollacott et al., 2018). These high levels are unlikely to be measurement errors given the favorable assay characteristics (Kleinberger et al., 2014) and low inter-plate and duplicate CVs. Elevated CSF sTREM2 levels are thought to reflect increased TREM2-dependent microglial activation, a hypothesis that is supported by more convincingly elevated levels in typical neuroinflammatory diseases such as multiple sclerosis (Piccio et al., 2008) and by a correlation between brain sTREM2 levels and microglial activity on TSPO-PET imaging in mouse models (Brendel et al., 2017). Our findings might therefore reflect a variable degree of microglial involvement specifically among GRN mutation carriers. The identification of subsets of carriers with more or less microglial activation would be highly valuable for patient stratification in inflammation-directed clinical trials. Interestingly, much variability has also been observed for the microglia-derived proteins YKL-40 and chitotriosidase (CHIT-1) in FTD (Abu-Rumeileh et al., 2019; Ockl et al., 2019; Woollacott et al., 2020) and future studies that elucidate the relationship between these proteins in FTD-GRN would be of interest.

Three presymptomatic GRN mutation carriers developed FTD after CSF collection, and cognitive decline was reported in one. Interestingly, 2 of these subjects with very high sTREM2 levels only developed symptoms several years after CSF collection, while 2 subjects with low sTREM2 levels declined within 2 years. It is tempting to speculate that increased microglial activity and accordingly, high sTREM2 levels, in the late-presymptomatic stage might delay disease onset. In mild cognitive impairment and AD, higher CSF sTREM2 levels have been associated with reduced rates of clinical decline and attenuated amyloid-β accumulation on amyloid PET imaging, suggesting that TREM2-related processes might play a protective role (Ewers et al., 2020; Ewers et al., 2019; Franzmeier et al., 2020). In line with these findings, increased microglial activation on TSPO-PET imaging predicted slower disease progression in (prodromal) AD (Hamelin et al., 2018). Such associations require further study in a much larger cohort of FTD-GRN patients, and could be highly relevant for clinical trial design as they could potentially confound outcome measures, i.e., slow progression rates could falsely be attributed to the study drug.

The positive correlation between sTREM2 levels and age is in line with previous studies (Ma et al., 2020; Piccio et al., 2016; Suárez-Calvet et al., 2016; Suárez-Calvet et al., 2019; Woollacott et al., 2018) and is thought to reflect physiological age-related microglial activity (Heneka et al., 2014; Kleinberger et al., 2017). Although we cannot rule out that co-existence of other (asymptomatic) neurodegenerative diseases such as AD might have affected sTREM2 levels in our cohort, several studies have found no correlation between sTREM2 levels and CSF amyloid-β (Piccio et al., 2016; Suárez-Calvet et al., 2016; Suárez-Calvet et al., 2019); therefore, the effect of concomitant amyloid pathology on sTREM2 levels in the present study is probably limited.

Neuroinflammation is thought to be the result of a highly complex and dynamic interaction between many factors (Bright et al., 2019). Different disease stages might be characterized by variable
degrees of microglial activation and subsequent sTREM2 shedding, making group comparisons difficult to interpret. This is exemplified by findings of elevated sTREM2 levels in preclinical and early-stage AD, followed by slightly attenuated levels in later disease stages (Liu et al., 2018; Ma et al., 2020; Suárez-Calvet et al., 2019). Longitudinal measurements of sTREM2 in FTD-GRN might provide insights into its dynamics over the course of disease as well as determine its value as a disease monitoring marker.

A major strength of this study is the inclusion of presymptomatic and symptomatic carriers of GRN and C9orf72 mutations, as opposed to clinically diagnosed FT patients, enabling investigation of well-defined, pathologically homogenous cohorts. Limitations include the relatively small sample size, which may have affected statistical power to detect group differences. Furthermore, the MMSE score might not be an optimal measure of disease severity in FTD, however it is a highly standardized instrument which we feel provides a suitable cognitive screening for this multicenter study. Finally, we cannot rule out that some subjects may have carried rare genetic variants in TREM2, which are known to affect sTREM2 levels (Kleingberger et al., 2014; Suárez-Calvet et al., 2019).

In conclusion, while sTREM2 is of limited diagnostic utility in FTD-GRN, its further study might help to elucidate the role of neuroinflammation in FTD pathogenesis. It would be interesting to further characterize the small number of GRN mutation carriers with very high sTREM2 levels and to investigate sTREM2 dynamics over the course of disease through longitudinal measurements.

Disclosure statement
C.H. collaborates with Denali Therapeutics, participated in one advisory board meeting of Biogen and received a speaker honorarium from Novartis and Roche. C.H. is chief advisor of ISAR Bioscience. The remaining authors declare no conflicts of interest.

Acknowledgements
This work was supported by 2 Memorabel grants from Delta- plan Dementia (The Netherlands Organisation for Health Research and Development and Alzheimer Nederland; grant numbers 733050813 and 733050103); The Bluefield Project to Cure Frontotemporal Dementia; the Dioraphite Foundation (grant number 1402 1300); the European Joint Programme – Neurodegenerative Disease Research (JPND, PREFrontALS); NIH (grant number AG017586); the Wyncote Foundation; Arking Family Fund; Invetstements d’avance (grant number ANR-11-INBS-0011); the Schörling Foundation - Swedish FTD Initiative, Swedish Research Council (2015-02926, 2018-02754, and 2019-02248; JPND GENFI-PROX), Swedish Alzheimer’s Foundation, Brain Foundation, Demensfonden, Stiftelsen för Gamla Tjänarinnor, Stohnes foundation, and Region Stockholm (ALP project).

Supplementary materials
Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.neurobiolaging.2021.02.024.

References


